ERBB2 and non-small cell lung carcinoma: The introduction of targeted therapies, including tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates like trastuzumab deruxtecan, has transformed treatment options for HER2-mutant NSCLC.